LifeMD, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US53216B1044
USD
3.73
0.17 (4.78%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.24 M

Shareholding (Mar 2025)

FII

6.85%

Held by 40 FIIs

DII

74.33%

Held by 21 DIIs

Promoter

0.56%

How big is LifeMD, Inc.?

22-Jun-2025

As of Jun 18, LifeMD, Inc. has a market capitalization of 618.58 million and reported net sales of 234.00 million with a net profit of -10.17 million over the latest four quarters. Shareholder's funds are at -5.49 million, and total assets amount to 72.46 million.

As of Jun 18, LifeMD, Inc. has a market capitalization of 618.58 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 234.00 million, while the sum of net profit for the same period is -10.17 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at -5.49 million, and the total assets amount to 72.46 million.

Read More

What does LifeMD, Inc. do?

22-Jun-2025

LifeMD, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $66 million and a net profit of $2 million. It has a market cap of $618.58 million and notable financial metrics, including a debt equity ratio of 6.65 and a return on equity of 436.41%.

Overview: <BR>LifeMD, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 66 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 2 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 618.58 Million (Micro Cap)<BR><BR>Key Metrics: <BR>Debt Equity: 6.65 <BR>Return on Equity: 436.41% <BR>Price to Book: -265.63<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Should I buy, sell or hold LifeMD, Inc.?

22-Jun-2025

Is LifeMD, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, LifeMD, Inc. shows a mildly bearish technical trend despite strong year-to-date and three-year performance, with mixed signals from indicators like the weekly MACD and Bollinger Bands.

As of 10 September 2025, the technical trend for LifeMD, Inc. has changed from sideways to mildly bearish. The weekly MACD is bearish, while the monthly MACD is bullish, indicating mixed signals. The Bollinger Bands and KST are both mildly bearish on a weekly and monthly basis, and Dow Theory also reflects a mildly bearish stance. Daily moving averages show a mildly bullish trend. <BR><BR>In terms of performance, LifeMD has outperformed the S&P 500 on a year-to-date basis with a return of 29.90% compared to the S&P 500's 12.22%, and over three years, it has significantly outperformed with a return of 179.57% against the S&P 500's 70.41%. Overall, the current technical stance is mildly bearish, with key indicators such as the weekly MACD and Bollinger Bands driving this view.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Operating profit has grown by an annual rate 11.30% of over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -23.04
2

The company has declared Positive results for the last 4 consecutive quarters

3

Risky - Negative Operating Profits

4

High Institutional Holdings at 53.14%

5

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 292 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

11.34

stock-summary
Return on Equity

274.64%

stock-summary
Price to Book

-163.95

Revenue and Profits:
Net Sales:
62 Million
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-38.85%
0%
-38.85%
6 Months
-70.51%
0%
-70.51%
1 Year
-39.45%
0%
-39.45%
2 Years
-51.93%
0%
-51.93%
3 Years
42.91%
0%
42.91%
4 Years
-6.05%
0%
-6.05%
5 Years
-53.26%
0%
-53.26%

LifeMD, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
64.36%
EBIT Growth (5y)
11.30%
EBIT to Interest (avg)
-23.04
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
6.65
Sales to Capital Employed (avg)
15.80
Tax Ratio
4.12%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
53.14%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-248.81
EV to EBIT
-75.89
EV to EBITDA
215.33
EV to Capital Employed
-31.66
EV to Sales
2.41
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 28 Schemes (18.26%)

Foreign Institutions

Held by 40 Foreign Institutions (6.85%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -5.33% vs 2.18% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -184.21% vs 850.00% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "62.20",
          "val2": "65.70",
          "chgp": "-5.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.90",
          "val2": "5.20",
          "chgp": "-63.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "0.60",
          "chgp": "16.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.60",
          "val2": "1.90",
          "chgp": "-184.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-14.60%",
          "val2": "38.70%",
          "chgp": "-5.33%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 39.34% vs 28.15% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -5.06% vs 60.44% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "212.50",
          "val2": "152.50",
          "chgp": "39.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.70",
          "val2": "-7.90",
          "chgp": "15.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.20",
          "val2": "2.60",
          "chgp": "-15.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.30",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-18.70",
          "val2": "-17.80",
          "chgp": "-5.06%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-76.00%",
          "val2": "-95.00%",
          "chgp": "1.90%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
62.20
65.70
-5.33%
Operating Profit (PBDIT) excl Other Income
1.90
5.20
-63.46%
Interest
0.70
0.60
16.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.60
1.90
-184.21%
Operating Profit Margin (Excl OI)
-14.60%
38.70%
-5.33%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -5.33% vs 2.18% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -184.21% vs 850.00% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
212.50
152.50
39.34%
Operating Profit (PBDIT) excl Other Income
-6.70
-7.90
15.19%
Interest
2.20
2.60
-15.38%
Exceptional Items
0.00
-0.30
100.00%
Consolidate Net Profit
-18.70
-17.80
-5.06%
Operating Profit Margin (Excl OI)
-76.00%
-95.00%
1.90%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 39.34% vs 28.15% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -5.06% vs 60.44% in Dec 2023

stock-summaryCompany CV
About LifeMD, Inc. stock-summary
stock-summary
LifeMD, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available